论文部分内容阅读
目的探讨c-erb-B2、拓扑异构酶Ⅱα(TopoⅡα)在乳腺癌组织中的表达及临床意义。方法采用免疫组化法检测110例乳腺癌石蜡切片标本中c-erb-B2和TopoⅡα的表达。结果 110例乳腺癌组织中,c-erb-B2阳性表达率为21.8%,TopoⅡα阳性表达率为56.4%。c-erb-B2表达与淋巴结转移状态、临床分期相关(P<0.01);TopoⅡα与肿瘤细胞雌激素受体(ER)状态相关(P<0.05)。TopoⅡα与c-erb-B2表达呈正相关(P<0.01)。结论 c-erb-B2、TopoⅡα在乳腺癌组织中的高表达与乳腺癌的发生发展密切相关,联合检测c-erb-B2、TopoⅡα对于乳腺癌的化疗具有指导意义,也是判断预后的重要指标。
Objective To investigate the expression of c-erb-B2 and topoisomerase Ⅱα (TopoⅡα) in breast cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of c-erb-B2 and TopoⅡα in 110 cases of breast cancer paraffin sections. Results The positive rate of c-erb-B2 in 110 cases of breast cancer was 21.8%, and the positive rate of TopoⅡα was 56.4%. The expression of c-erb-B2 was correlated with lymph node metastasis status and clinical stage (P <0.01). TopoⅡα was correlated with estrogen receptor (ER) status of tumor cells (P <0.05). TopoⅡα and c-erb-B2 expression was positively correlated (P <0.01). Conclusions The high expression of c-erb-B2 and TopoⅡα in breast cancer is closely related to the occurrence and development of breast cancer. The combined detection of c-erb-B2 and TopoⅡα may play an important guiding role in the chemotherapy of breast cancer and is an important index for prognosis.